Search Results (2)

Background: Three-dimensional printing (3DP) is a promising technology for advancing pharmaceutical research by enabling the production of personalized drug products. However, its progress has been hindered by the conventional trial-and-error approach to excipient selection and optimization. Methods: In this study, the blend module was employed to determine the miscibility parameters—mixing energy (E_mix) and Flory–Huggins interaction parameter (χ) to find the right excipients and drug–excipient ratio and examine the incorporation of plasticizers and lipids to enhance printability. Furthermore, molecular dynamics (MD) simulations were employed to calculate the cohesive energy density (CED) for predicting the dissolution behavior of 3DP formulations. Results: Data from 51 formulations were analyzed, enabling correlation and experimental validation of the in silico predictions. The predicted miscibility values demonstrated a strong correlation with experimental printability results. Furthermore, using a miscibility parameter, it was possible to accurately forecast minor changes in the drug-to-excipient ratio, plasticizer/lipid concentration, and hot-melt extrusion (HME) temperature that affect printability. Hydrophilic carriers exhibited lower CED values corresponding to faster drug release. In contrast, more hydrophobic carriers revealed high CED values, indicating stronger drug entrapment and sustained release. Conclusions: The miscibility parameters and MD-simulated CED values provide a practical framework for early-stage, high-throughput excipient screening. Overall, in silico prediction offers a viable strategy for modeling the entire 3DP workflow, minimizing the need for trial-and-error experimentation, and thereby accelerating the clinical translation of 3DP drug delivery systems. Full article

The presence of blood–brain barrier (BBB) and/or blood–brain–tumor barriers (BBTB) is one of the main obstacles to effectively deliver therapeutics to our central nervous system (CNS); hence, the outcomes following treatment of malignant brain tumors remain unsatisfactory. Although some approaches regarding BBB disruption or drug modifications have been explored, none of them reach the criteria of success. Convention-enhanced delivery (CED) directly infuses drugs to the brain tumor and surrounding tumor infiltrating area over a long period of time using special catheters. Focused ultrasound (FUS) now provides a non-invasive method to achieve this goal via combining with systemically circulating microbubbles to locally enhance the vascular permeability. In this review, different approaches of delivering therapeutic agents to the brain tumors will be discussed as well as the characterization of BBB and BBTB. We also highlight the mechanism of FUS-induced BBB modulation and the current progress of this technology in both pre-clinical and clinical studies. Full article